Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates
The month of April was a mixed one for regulatory approvals. The Food and Drug Administration delayed approvals for at least three treatment candidates. New molecular entity, or NME, approvals, a measure of innovation in drug research, tapered to merely one for the month.
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 784 companies set new 52-week lows.
Amicus Therapeutics Earnings Conference Call Is Coming Up, Here’s What You Need To Know
Amicus Therapeutics (NASDAQ:FOLD) will host a conference call at 08:30 AM ET on May 9, 2022, to discuss Q1 2022 earnings results.
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday, 581 stocks hit new 52-week lows.
Interesting Highlights From Today's 52-Week Lows
Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.
Amicus Announces Issuance Of New US Composition Of Matter Patent For Galafold
Amicus Therapeutics (NASDAQ:FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, announced today that the United States Patent and Trademark
Amicus Therapeutics Highlights Long-Term Data From Phase 1/2 Study Of AT-GAA In Pompe Disease At 2022 MDA Clinical & Scientific Conference
Meaningful and Durable Responses in Key Endpoints of Six-Minute Walk and Forced Vital Capacity
for ERT-Naïve and ERT-Experienced Patients Out to 3 Years
Consistent Reduction in Biomarkers Continue to
SVB Leerink Maintains Outperform on Amicus Therapeutics, Lowers Price Target to $14
SVB Leerink analyst Joseph Schwartz maintains Amicus Therapeutics (NASDAQ:FOLD) with a Outperform and lowers the price target from $16 to $14.
Gene Therapy Player Amicus Therapeutics Terminates SPAC Merger, Shares Fall
Amicus Therapeutics Inc (NASDAQ: FOLD) has terminated its plans to spin off its gene therapy assets, citing 'existing market conditions.'